Neuromedin U Receptor (NMUR)

R-PSOP is a potent and selective nonpeptidic antagonist of the neuropeptide receptor NMUR2. With binding affinities (Kis) of 52 nM for human and 32 nM for rat NMUR2, R-PSOP demonstrates effective receptor inhibition. Its moderate central nervous system penetration makes it a valuable tool for investigating eating disorders, obesity, pain mechanisms, and stress-related disorders in research settings.

CPN-219 is a next-generation hexapeptidic agonist specifically targeting NMUR2. It demonstrates a selective and dose-dependent activation of NMUR2, with an EC50 value of 2.2 nM. This compound is invaluable for research applications aimed at understanding the physiological roles of NMUR2 in various biological processes.

CPN-116 is a selective agonist of the neuromedin U receptor 2 (NMUR2), which plays a critical role in the regulation of appetite and energy homeostasis. This compound has demonstrated potential biological activity in modulating metabolic processes, making it a valuable tool for research into obesity and related metabolic disorders. Its ability to activate NMUR2 may provide insights into developing therapeutic strategies for weight management and obesity treatment.

3'-Methoxyflavonol is a selective agonist of the neuromedin U 2 receptor (NMU2R). It plays a significant role in various physiological processes, including modulation of appetite and anxiety behavior. This compound is useful in research applications focused on neuropeptide signaling pathways and their implications in metabolic and behavioral disorders.

CPN-267 is a selective agonist of the neuromedin U receptor 1 (NMUR1), demonstrating an EC50 of 0.25 nM. It has been shown to suppress body weight gain in mouse models, making it a valuable tool for research on obesity and related metabolic disorders.

Neuromedin U (rat) is a 23-amino acid neuropeptide that acts as an agonist for the NMUR2 receptor. This receptor-mediated action is crucial for the modulation of various physiological processes, including energy homeostasis, stress response, and pain perception. Neuromedin U is valuable for research investigating neuropeptide signaling pathways and their implications in metabolic disorders and stress-related conditions.

CPN-351 is a selective antagonist of the human neuropeptide FF receptor 1 (NMUR1), exhibiting a pA2 of 7.35. Its antagonistic potency towards NMUR1 is significantly greater than its effect on NMUR2, being approximately ten times more effective. CPN-351 is a valuable tool for investigating inflammatory processes and the role of neuropeptide signaling in various biological systems.

NY0116 is an agonist of the neuromedin U receptor 2 (NMUR2), exhibiting an EC50 of 13.61 μM for hNMUR2 and 27.76 μM for hNMUR1. This compound effectively reduces cAMP levels while enhancing calcium signaling in HEK293 cells stably expressing NMUR2. NY0116 is suitable for research applications involving neuropeptide signaling pathways and their physiological implications.